Prospective study finds mupirocin resistance prevalence of 10.7% in S. aureus isolates, suggesting continued viability for decolonization protocols.
Background The emergence of mupirocin resistance in both Methicillin-Resistant Staphylococcus aureus (MRSA) and Methicillin-Sensitive Staphylococcus aureus (MSSA) poses a significant challenge for antimicrobial therapy and nasal decolonization. Historically, mupirocin has been effective against Staphylococcus aureus strains, but due to the lack of routine susceptibility testing for this agent, its prevalence is not fully understood. However, it has been suggested there is an increasing prevalence of resistance across hospitals. In this prospective study, we are determining the prevalence of mupirocin in MSSA and MRSA isolated from multiple sources of infection. Methods 913 isolates of S. aureus (397=MRSA, 516=MSSA) were isolated from active infections from multiple sources, including respiratory, body fluids, wounds, etc. Tested isolates were collected across a multi-system facility from October 2023 – August 2024, Methicillin resistance was determined by broth microdilution (BMD) for oxacillin and/or cefoxitin screening. Mupirocin screening was performed using a 200µg mupirocin disk diffusion following the disk-based guidelines of the current clinical laboratory standards for high-level of resistance (HLR) and absence of HLR (AHLR). Results Out of 913 S. aureus isolates, 815 (89.3%) resulted as AHLR for mupirocin (susceptible), and 98 (10.7%) resulted as HLR for mupirocin (resistant). HLR among MRSA was 17.6%, and 5.4% for MSSA. AHLR was observed in 82.4% of MRSA and 94.6% of MSSA Conclusion The total prevalence for HLR to mupirocin in circulating infective strains from inpatient and outpatient was 7%. The distribution of HLR between MRSA and MSSA was statistically similar, with 43% and 57%, respectively. This distribution indicates there is no correlation between methicillin resistance and mupirocin resistance; that was expected since both resistance mechanisms and agents are different. With a low prevalence of HLR, mupirocin is a viable option for decolonization protocols in clinical settings. Disclosures All Authors: No reported disclosures
No takes yet. Share an insight, caveat, or question.
Flowers et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: